This content is from: Premium

ValueAct Identifies Possible New Activist Target

The hedge fund firm also revealed another small new position.

   Photo credit: Bigstock Photo Jeffrey Ubben’s ValueAct Capital has set its sights on a potential new target.The San Francisco activist hedge fund firm disclosed late Thursday that it owns 7.7 million shares of Bioverativ, or 7.1 percent of the total shares.The filing came just a couple of days after the hedge

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content